Ajit Jadhav

Ajit Jadhav

Auto-generated profile, based on publicly available information

Ajit Jadhav

National Center for Advancing Translational Sciences, Bethesda, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2016 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
MWMingxun Wang
Mingxun Wang
JCJeremy J Carver
Jeremy J Carver
VPVanessa Phelan
Vanessa Phelan
LSLaura Sanchez
Laura Sanchez
NGNeha Garg
Neha Garg
NBNuno Bandeira
Nuno Bandeira
GNPS is an open-access community-curated analysis platform for sharing natural product mass spectrometry data that enables continuous, automatic reanalysis of deposited 'living' data sets. The potential of the diverse chemistries present in natural products (NP) for biotechnology and medicine remains untapped because NP databases are not searchable with raw data and the NP community has no way to share data other than in published papers. Although mass spectrometry (MS) techniques are well-suited to high-throughput characterization of NP, there is a pressing need for an infrastructure to enable sharing and curation of data. We present Global Natural Products Social Molecular Networking (GNPS; http://gnps.ucsd.edu ), an open-access knowledge base for community-wide organization and sharing of raw, processed or identified tandem mass (MS/MS) spectrometry data. In GNPS, crowdsourced curation of freely available community-wide reference MS libraries will underpin improved annotations. Data-driven social-networking should facilitate identification of spectra and foster collaborations. We also introduce the concept of 'living data' through continuous reanalysis of deposited data.

1 August 2006 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JIJames Inglese
James Inglese
DADouglas S. Auld
Douglas S. Auld
AJAjit Jadhav
Ajit Jadhav
RJRonald L. Johnson
Ronald L. Johnson
ASAnton Simeonov
Anton Simeonov
CAChristopher P. Austin
Christopher P. Austin
High-throughput screening (HTS) of chemical compounds to identify modulators of molecular targets is a mainstay of pharmaceutical development. Increasingly, HTS is being used to identify chemical probes of gene, pathway, and cell functions, with the ultimate goal of comprehensively delineating relationships between chemical structures and biological activities. Achieving this goal will require methodologies that efficiently generate pharmacological data from the primary screen and reliably profile the range of biological activities associated with large chemical libraries. Traditional HTS, which tests compounds at a single concentration, is not suited to this task, because HTS is burdened by frequent false positives and false negatives and requires extensive follow-up testing. We have developed a paradigm, quantitative HTS (qHTS), tested with the enzyme pyruvate kinase, to generate concentration–response curves for >60,000 compounds in a single experiment. We show that this method is precise, refractory to variations in sample preparation, and identifies compounds with a wide range of activities. Concentration–response curves were classified to rapidly identify pyruvate kinase activators and inhibitors with a variety of potencies and efficacies and elucidate structure–activity relationships directly from the primary screen. Comparison of qHTS with traditional single-concentration HTS revealed a high prevalence of false negatives in the single-point screen. This study demonstrates the feasibility of qHTS for accurately profiling every compound in large chemical libraries (>10 5 compounds). qHTS produces rich data sets that can be immediately mined for reliable biological activities, thereby providing a platform for chemical genomics and accelerating the identification of leads for drug discovery.

20 April 2015 in Nature
Verified
Journal Article
Open access
PDF file
FNFadi J. Najm
Fadi J. Najm
MMMayur Madhavan
Mayur Madhavan
AZAnita Zaremba
Anita Zaremba
ESElizabeth Shick
Elizabeth Shick
RKRobert T. Karl
Robert T. Karl
PTPaul J. Tesar
Paul J. Tesar
Two drugs, miconazole and clobetasol, have functions that modulate differentiation of oligodendrocyte progenitor cells directly, enhance remyelination, and significantly reduce disease severity in mouse models of multiple sclerosis. Multiple sclerosis is characterized by an autoimmune response and failure of remyelination in the brain due to defects in differentiation of myelin-producing cells from oligodendrocyte progenitor cells. Most current treatments target the immune system. Paul Tesar and colleagues screened for compounds that can enhance oligodendrocyte maturation from mouse pluripotent epiblast stem-cell-derived oligodendrocyte progenitors. They found two drugs — miconazole (an antifungal) and clobetasol (a steroid) — that enhance myelin production in vivo in mouse models of multiple sclerosis and enhanced the differentiation of human oligodendrocytes progenitors in vitro. Mechanistically, these compounds appear to target both the immune response and oligodendrocyte progenitor cells. Multiple sclerosis involves an aberrant autoimmune response and progressive failure of remyelination in the central nervous system. Prevention of neural degeneration and subsequent disability requires remyelination through the generation of new oligodendrocytes, but current treatments exclusively target the immune system. Oligodendrocyte progenitor cells are stem cells in the central nervous system and the principal source of myelinating oligodendrocytes1. These cells are abundant in demyelinated regions of patients with multiple sclerosis, yet fail to differentiate, thereby representing a cellular target for pharmacological intervention2. To discover therapeutic compounds for enhancing myelination from endogenous oligodendrocyte progenitor cells, we screened a library of bioactive small molecules on mouse pluripotent epiblast stem-cell-derived oligodendrocyte progenitor cells3,4,5. Here we show seven drugs function at nanomolar doses selectively to enhance the generation of mature oligodendrocytes from progenitor cells in vitro. Two drugs, miconazole and clobetasol, are effective in promoting precocious myelination in organotypic cerebellar slice cultures, and in vivo in early postnatal mouse pups. Systemic delivery of each of the two drugs significantly increases the number of new oligodendrocytes and enhances remyelination in a lysolecithin-induced mouse model of focal demyelination. Administering each of the two drugs at the peak of disease in an experimental autoimmune encephalomyelitis mouse model of chronic progressive multiple sclerosis results in striking reversal of disease severity. Immune response assays show that miconazole functions directly as a remyelinating drug with no effect on the immune system, whereas clobetasol is a potent immunosuppressant as well as a remyelinating agent. Mechanistic studies show that miconazole and clobetasol function in oligodendrocyte progenitor cells through mitogen-activated protein kinase and glucocorticoid receptor signalling, respectively. Furthermore, both drugs enhance the generation of human oligodendrocytes from human oligodendrocyte progenitor cells in vitro. Collectively, our results provide a rationale for testing miconazole and clobetasol, or structurally modified derivatives, to enhance remyelination in patients.

23 March 2018 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
TOTudor I. Oprea
Tudor I. Oprea
CBCristian G. Bologa
Cristian G. Bologa
SBSøren Brunak
Søren Brunak
ACAllen Campbell
Allen Campbell
GGGregory N Gan
Gregory N Gan
GZGergely Zahoránszky-Köhalmi
Gergely Zahoránszky-Köhalmi

27 January 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
LGLesley A. Mathews Griner
Lesley A. Mathews Griner
RGRajarshi Guha
Rajarshi Guha
PSPaul Shinn
Paul Shinn
RYRyan M. Young
Ryan M. Young
JKJonathan M. Keller
Jonathan M. Keller
CTCraig J. Thomas
Craig J. Thomas
Significance: The treatment of cancer is highly reliant on drug combinations. Next-generation, targeted therapeutics are demonstrating interesting single-agent activities in clinical trials; however, the discovery of companion drugs through iterative clinical trial-and-error is not a tenable mechanism to prioritize clinically important combinations for these agents. Herein we describe the results of a large, high-throughput combination screen of the Bruton’s tyrosine kinase inhibitor ibrutinib versus a library of nearly 500 approved and investigational drugs. Multiple ibrutinib combinations were discovered through this study that can be prioritized for clinical examination.

27 April 2011 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
RHRuili Huang
Ruili Huang
NSNoel Southall
Noel Southall
YWYuhong Wang
Yuhong Wang
AYAdam Yasgar
Adam Yasgar
PSPaul Shinn
Paul Shinn
CAChristopher P. Austin
Christopher P. Austin
Resources from the National Institutes of Health Chemical Genomics Center include a database and a physical collection of approved drugs.